Synopsis Clinical evidence suggests that nivolumab combined with ipilimumab is an effective treatment for patients with asymptomatic, untreated brain metastases from melanoma. The present study aims to evaluate the efficacy and safety of nivolumab plus ipilimumab in patients with melanoma who had untreated brain metastases. This week’s “ MED FACT ” discusses a clinical study from The New England Journal of Medicine, “ Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain ”. Aug 2018.
Author s : Hussein A. Tawbi; Peter A. Forsyth; Alain Algazi; et al. Key Takeaways: The Combination of nivolumab and ipilimumab shows 57% intracranial clinical benefits than previously reported with ipilimumab alone Objective: To evaluate the efficacy and safety of nivolumab plus ipilimumab in patients with melanoma who have asymptomatic, untreated brain metastases Study Type: Open-label,…
